Soft-tissue sarcomas. Future perspectives.
Although the previous outlook for patients with soft-tissue tumors was poor, in recent years advances have been made in earlier recognition and management of soft-tissue sarcomas. Advances include improved clinical pathologic correlation and clinical staging, as well as improved concept of what constitutes adequate surgical management. In addition, recent advances in surgical adjuvant treatment programs promise better results. Moreover, a better understanding of the biology of cancer and the development of sophisticated techniques of molecular biology should lead to more effective treatment.
Sim
F H
FH
Department of Orthopedics, Mayo Clinic, Rochester, MN 55905.
Edmonson
J H
JH
Wold
L E
LE
D000276:Adjuvants, Immunologic; D017024:Chemotherapy, Adjuvant / Q000379:methods / Q000639:trends; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D005544:Forecasting; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000639:trends; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D009367:Neoplasm Staging; D011878:Radiotherapy / Q000379:methods / Q000639:trends; D012509:Sarcoma / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D012680:Sensitivity and Specificity; D012983:Soft Tissue Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D015996:Survival Rate; D014057:Tomography, X-Ray Computed / Q000639:trends; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic